SCHEMBL5086032

SCHEMBL5086032

CCC(OC(=O)C(C)(C)C)(C(C)O[Si](c1ccccc1)(c1ccccc1)C(C)(C)C)n1cnc2c(N)ncnc21

nearest known ligand 0.42

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PI4KA P42356 4/20 0.42
PI4K2B Q8TCG2 4/20 0.42
PI4K2A Q9BTU6 4/20 0.42
PI4KB Q9UBF8 4/20 0.42
EGFR P00533 3/20 0.38
ABCB11 O95342 1/20 0.36
POLA1 P09884 1/20 0.36
POLG P54098 1/20 0.36
FAP Q12884 1/20 0.36
SLC22A6 Q4U2R8 1/20 0.36
ADORA2A P29274 3/20 0.35
ADORA1 P30542 2/20 0.35
ADORA2B P29275 1/20 0.35
ALDH1A1 P00352 1/20 0.35
LMNA P02545 1/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5083668 0.83 PI4KA (0.47) PI4KAPI4K2BPI4K2API4KBEGFR
SCHEMBL5086028 0.73 PDE2A (0.42) ALDH1A1LMNASMN1; SMN2
SCHEMBL5083010 0.71 PI4KA (0.54) PI4KAPI4K2BPI4K2API4KBABCB11
SCHEMBL14175392 0.70 ABCB11 (0.42) EGFRABCB11POLA1POLGFAP
SCHEMBL5083662 0.69 PDE2A (0.47) ALDH1A1LMNASMN1; SMN2
SCHEMBL5083002 0.69 PI4KA (0.53) PI4KAPI4K2BPI4K2API4KBADORA2A
SCHEMBL5083628 0.66 ADORA2A (0.49) PI4KAPI4K2BPI4K2API4KBEGFR
SCHEMBL983794 0.66 PI4KA (0.65) PI4KAPI4K2BPI4K2API4KBEGFR
SCHEMBL5179152 0.66 ADORA2A (0.44) PI4KAPI4K2BPI4K2API4KBADORA2A
SCHEMBL12948653 0.64 PI4KA (0.59) PI4KAPI4K2BPI4K2API4KBEGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7388002-B2 Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases BIOCRYST PHARMACEUTICALS, INC. (US) 2008-06-17 US disclosed
US-20060122391-A1 Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases BIOCRYST PHARMACEUTICALS, INC. (US) 2006-06-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060122391-A1 Nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases POLR2H, NSUN2, POLR2E PI4KA 2684/4885PI4K2B 1893/4885PI4K2A 2678/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.